Article
Oncology
Harrison K. Chinn, Jennifer L. Gardell, Lisa R. Matsumoto, Kevin P. Labadie, Tara N. Mihailovic, Nicole A. P. Lieberman, Amira Davis, Venu G. Pillarisetty, Courtney A. Crane
Summary: This study demonstrates the engineering of human macrophages to conditionally express genes under hypoxic conditions, allowing for localized gene delivery in cancer. The engineered macrophages were able to express therapeutic proteins in a controlled manner, making them ideal vehicles for delivering payloads in hypoxic tissues.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Nicoletta Nastasi, Amada Pasha, Gennaro Bruno, Angela Subbiani, Laura Pietrovito, Angela Leo, Lucia Scala, Lorena de Simone, Gabriella Casazza, Federica Lunardi, Maria Letizia Taddei, Angela Tamburini, Annalisa Tondo, Claudio Favre, Maura Calvani
Summary: Osteosarcoma is a common malignant bone tumor that mainly affects children and adolescents. Standard treatment includes surgery and chemotherapy, but the effectiveness is limited for metastatic or recurrent cases. This study investigates the efficacy of mifamurtide and identifies interleukin-10 as a possible target to improve its effectiveness. The synergistic use of mifamurtide and an anti-IL-10 antibody significantly increases cell death and reduces metastasis in a mouse model. The findings suggest that combining mifamurtide with an anti-IL-10 antibody may improve outcomes for osteosarcoma patients.
Article
Oncology
Shifaa M. Abdin, Daniela Paasch, Michael Morgan, Nico Lachmann
Summary: Understanding the role of immune cells in disease treatment has led to advancements in immunotherapies, particularly genetic engineering in cancer immunotherapy. Recent studies show that introducing chimeric antigen receptors into macrophages may broaden the applications for better tumor control. This review discusses the role of macrophages in cancer therapy, focusing on genetic engineering and CAR platforms to optimize treatment strategies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Tereza Andreou, Jennifer Williams, Rebecca J. Brownlie, Robert J. Salmond, Erica Watson, Gary Shaw, Alan Melcher, Heiko Wurdak, Susan C. Short, Mihaela Lorger
Summary: The study focuses on using hematopoietic stem cell (HSC) gene therapy to target tumor-infiltrating myeloid cells in glioblastoma (GBM), achieving specific gene delivery through a lentiviral vector, blocking TGFβ in combination with radiotherapy significantly reduced tumor burden and prolonged survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Chemistry, Multidisciplinary
Chao Wan, Yajie Sun, Yan Hu, Jing Huang, Lisen Lu, Yanan Gao, Huaduan Zi, Qianyuan He, Jinfeng Sun, Jonathan F. Lovell, Kunyu Yang, Honglin Jin
Summary: A therapeutic peptide hydrogel developed in this study effectively kills tumor cells, reshapes the tumor microenvironment, and enhances the efficacy of immune checkpoint blockade therapy, leading to prolonged survival.
Article
Oncology
Alexander Chehrazi-Raffle, Luis Meza, Marice Alcantara, Nazli Dizman, Paulo Bergerot, Nicholas Salgia, JoAnn Hsu, Nora Ruel, Sabrina Salgia, Jasnoor Malhotra, Ewa Karczewska, Marcin Kortylewski, Sumanta Pal
Summary: This study found that specific plasma cytokines were associated with clinical benefit in patients with renal cell carcinoma receiving VEGF-TKI or ICI therapy. These findings support further investigation into plasma cytokines as potential biomarkers for renal cell carcinoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Mark Sorin, Elham Karimi, Morteza Rezanejad, Miranda W. Yu, Lysanne Desharnais, Sheri A. C. McDowell, Samuel Dore, Azadeh Arabzadeh, Valerie Breton, Benoit Fiset, Yuhong Wei, Roni Rayes, Michele Orain, Francois Coulombe, Venkata S. K. Manem, Andreanne Gagne, Daniela F. Quail, Philippe Joubert, Jonathan D. Spicer, Logan A. Walsh
Summary: This study used imaging mass cytometry to characterize the tumor and immunological landscape in non-small cell lung cancer patients receiving immunotherapy. They identified cellular states and interactions associated with improved treatment efficacy and found that CXCL13 expression is correlated with treatment response. The results were validated in preclinical mouse models, demonstrating that recombinant CXCL13 enhances anti-PD-1 therapy response.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Gabrielle Leclercq, Helene Haegel, Alberto Toso, Tina Zimmermann, Luke Green, Nathalie Steinhoff, Johannes Sam, Vesna Pulko, Anneliese Schneider, Anna Maria Giusti, John Challier, Anne Freimoser-Grundschober, Laurent Lariviere, Alex Odermatt, Martin Stern, Pablo Umana, Marina Bacac, Christian Klein
Summary: This study aimed to identify small molecules that can reduce cytokine release while maintaining T cell-mediated tumor killing. By screening a library of FDA-approved kinase inhibitors, mTOR, JAK, and Src kinase inhibitors were found to modulate cytokine release. Further in vitro and in vivo experiments confirmed these findings and supported the evaluation of these inhibitors as a treatment to prevent cytokine release syndrome (CRS).
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Engineering, Biomedical
Khaga R. Neupane, Geraldine S. Ramon, Brock Harvey, Byeong Chun, Surya P. Aryal, Abdullah A. Masud, J. Robert McCorkle, Jill M. Kolesar, Peter M. Kekenes-Huskey, Christopher I. Richards
Summary: Tumor-associated macrophages in the tumor microenvironment can switch from a pro-tumoral M2-like phenotype to an anti-tumoral M1-like phenotype. Programmed nanovesicles, engineered from cellular membranes with specific properties, can be used to modulate immune cell polarization and enhance immune cell reprogramming toward a proinflammatory phenotype.
ADVANCED HEALTHCARE MATERIALS
(2023)
Review
Oncology
Theo Accogli, Melanie Bruchard, Frederique Vegran
Summary: CD4 T lymphocytes play a crucial role in the anti-tumor response, which can be influenced by cytokines present in the microenvironment of tumors. Understanding the impact of tumors and anti-cancer therapies on cytokines and CD4 T lymphocytes is essential in immunotherapy research aiming to enhance the anti-tumor response.
Article
Oncology
Mathieu Larroquette, Jean-Philippe Guegan, Benjamin Besse, Sophie Cousin, Maxime Brunet, Sylvestre Le Moulec, Francois Le Loarer, Christophe Rey, Jean-Charles Soria, Fabrice Barlesi, Alban Bessede, Jean-Yves Scoazec, Isabelle Soubeyran, Antoine Italiano
Summary: This study investigated the predictive value of tumor-associated macrophages (TAMs) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) and characterized their transcriptomic profiles. The results showed that low intratumoral CD163+ cell infiltration was associated with longer progression-free survival (PFS) and overall survival (OS) under ICB treatment. The transcriptomic analyses identified potential targets to alter TAM recruitment/polarization and highlighted the complexity of the CSF1R pathway, which may not be a suitable target to improve ICB efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Chemistry, Analytical
Yanyun Fang, Yawei Yan, Shiyi Bi, Yingfei Wang, Yue Chen, Peipei Xu, Huangxian Ju, Ying Liu
Summary: In this study, a photo detachable DNA-copolymer nanocage was designed to screen the activities of T cells for the success of T-cell therapy. The DNA-copolymer nanocage on the cell membrane encapsulated a single T cell and the secretion of cytokine interferon-gamma (IFN-gamma) was monitored to indicate individual T-cell activity. The selected active T cells showed improved capabilities for downstream cell activation and cancer cell killing.
ANALYTICAL CHEMISTRY
(2022)
Article
Oncology
Laia Puig-Blasco, Krzysztof B. Piotrowski, Signe R. Michaelsen, Nicolai S. Bager, Ausrine Areskeviciutie, Marie-Louise Thorseth, Xiao-Feng Sun, Ulrich Auf Dem Keller, Bjarne W. Kristensen, Daniel H. Madsen, Sebastian P. Gnosa, Marie Kveiborg
Summary: Upregulation of ADAM15 in rectal cancer tissues was observed. ADAM15 was found to enhance tumor formation in mouse models. ADAM15 deficiency increased immune cell infiltration, including dendritic cells, macrophages, and T cells, in tumors. Targeting ADAM15 may enhance immune cell infiltration and improve immunotherapy efficacy in colorectal tumors.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Immunology
Mengyuan Li, Ping Jiang, Shuhua Wei, Junjie Wang, Chunxiao Li
Summary: Recent studies have shown that tumor-associated macrophages play a crucial role in tumor initiation and progression as the most abundant stromal cells in the tumor microenvironment. The proportion of macrophages in the tumor microenvironment is associated with cancer prognosis. These macrophages can polarize into anti-tumorigenic and pro-tumorigenic phenotypes, exerting opposing effects on tumor progression. Additionally, there is extensive communication between tumor-associated macrophages and other immune cells, impacting tumor development and treatment outcomes. Targeting the molecules and signaling pathways involved in these interactions can be a potential immunotherapeutic strategy for malignant tumors.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Lupita S. Lopez, Rachel H. Ng, Neena Leggett, Vanessa D. Jonsson, Jelani C. Zarif, Peter P. Lee, Xiuli Wang, Catalina Martinez, Tanya B. Dorff, Stephen J. Forman, Saul J. Priceman
Summary: This study reveals an alternative mechanism by which the combination of CAR T cells and immune checkpoint blockade modulates the immune landscape of solid tumors to enhance therapeutic efficacy of CAR T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)